好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Treatment of Headache with Occipital Nerve Blocks: Comparison Trial of Anesthetic with or Without Dexamethasone
Headache
P6 - Poster Session 6 (5:00 PM-6:00 PM)
15-016

This double-blind study compares the effectiveness of dexamethasone+anesthetic to anesthetic alone in occipital nerve blocks (ONBs), for treatment of headache. 

ONBs are commonly used for treating headache disorders. Few small randomized trials have investigated the benefit of adding corticosteroids to anesthetic for ONBs, and these studies did not demonstrate a large effect of steroids on outcomes. However, no study has assessed the benefit of non-particulate steroids (e.g., dexamethasone), which have lower rates of complication than particulate steroids, allow for better blinding, and have been shown to prolong duration of other types of peripheral nerve blocks.

118 adult subjects considered stable on other preventatives presented for bilateral combined greater/lesser ONBs for a variety of headaches (cluster headache excluded). Participants were randomized to receive either 2 mL of bupivacaine 0.5% (5 mg/mL), 0.5 mL of lidocaine 1% (10 mg/mL), and 0.5 mL of dexamethasone (10 mg/mL) or 2 mL of bupivacaine 0.5% (5 mg/mL), 0.5 mL of lidocaine 1% (10 mg/mL), and 0.5 mL of normal saline 0.9% at each injection site. Telephone follow-up was 1, 2, and 4 weeks after procedure. Primary outcome was the number of weekly headache days at each follow-up visit.

60 participants received dexamethasone+anesthetic; 58 received anesthetic alone. Both groups reported reduction in headache days compared to baseline at all three visits, with no significant difference between groups. Week 1: -1.9 w/ dexamethasone vs. -1.8 w/o dexamethasone, p=0.84. Week 2: -2.3 for both groups, p= 0.90. Week 4: -2.5 for both groups, p= 0.99.

This study did not show a significant reduction in weekly headache days when non-particulate steroids were added to ONBs. This is consistent with current recommendations regarding steroid use for ONBs in the treatment of headache (excluding cluster headache).

Authors/Disclosures
Carrie E. Robertson, MD, FAAN (Mayo Clinic)
PRESENTER
Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Linpharma. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Satsuma. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apeya. Dr. Robertson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Robertson has received research support from Biohaven/Pfizer. Dr. Robertson has received publishing royalties from a publication relating to health care. Dr. Robertson has received personal compensation in the range of $500-$4,999 for serving as a Research consultant with University of Minnesota.
Stephanie Steel, MD (Mayo Clinic) Dr. Steel has received publishing royalties from a publication relating to health care.
Jennifer Stern, MD (Mayo Clinic) An immediate family member of Dr. Stern has stock in Emmyon, Inc.. The institution of an immediate family member of Dr. Stern has received research support from NIH.
Mark A. Whealy, MD (Mayo Clinic Department of Neurology) Dr. Whealy has received publishing royalties from a publication relating to health care.
Krista Burke, NP (Mayo Clinic) Mrs. Burke has nothing to disclose.
Chia-Chun Chiang, MD (Mayo Clinic) Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aruene Corporation . Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Chiang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. The institution of Dr. Chiang has received research support from American Heart Association. The institution of Dr. Chiang has received research support from Lundbeck. The institution of Dr. Chiang has received research support from Pfizer.
F. M. Cutrer, MD (Mayo Clinic) Dr. Cutrer has received publishing royalties from a publication relating to health care.
Narayan R. Kissoon, MD Dr. Kissoon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex Pharmaceuticals. The institution of Dr. Kissoon has received research support from Nevro Corporation. The institution of Dr. Kissoon has received research support from Novo Nordisc Foundation. The institution of Dr. Kissoon has received research support from Shiratronics. Dr. Kissoon has received publishing royalties from a publication relating to health care.